A risk score for predicting mortality in patients with asymptomatic mild to moderate aortic stenosis

Heart

Volumn 98, Issue 5, 2012, Pages 377-383

  Holme, Ingar ^a   Pedersen, Terje R ^a   Boman, Kurt ^b   Egstrup, Kenneth ^c   Gerdts, Eva ^d,e   Kesäniemi, Y Antero ^f,g   Malbecq, William ^h   Ray, Simon ⁱ   Rossebø, Anne B ^a   Wachtell, Kristian ^j   Willenheimer, Ronnie ^k   Gohlke Bärwolf, Christa ^l  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UMEÅ UNIVERSITY   (Sweden)

^c SVENDBORG HOSPITAL   (Denmark)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f UNIVERSITY OF OULU   (Finland)

^g OULU UNIVERSITY HOSPITAL   (Finland)

^h MSD Europe Inc   (Belgium)

ⁱ MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^j Rigshospitalet   (Denmark)

^k LUND UNIVERSITY   (Sweden)

^l UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; C REACTIVE PROTEIN; EZETIMIBE PLUS SIMVASTATIN; PLACEBO;

ACCURACY; ADULT; AGE; AGED; AORTA STENOSIS; ARTICLE; CALIBRATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENDER; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SMOKING;

AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; ECHOCARDIOGRAPHY, DOPPLER; HUMANS; MIDDLE AGED; NORWAY; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84857112412     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300475     Document Type: Article

References (25)

1. Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999;16:9-13. (Pubitemid 29336425)
2. Miceli A, Bruno VD, Capoun R, et al. Mild renal dysfunction in patients undergoing cardiac surgery as a new risk factor for EuroSCORE. Heart 2011;97:362-5.
3. Ambler G, Omar RZ, Royston P, et al. Generic, simple risk stratification model for heart valve surgery. Circulation 2005;112:224-31. (Pubitemid 40982305)
4. Anderson RP. First publication from the Society of Thoracic Surgeons National Database. Ann Thorac Surg 1994;57:6-7. (Pubitemid 24047682)
5. Le Tourneau T, Pellikka PA, Brown ML, et al. Clinical outcome of asymptomatic severe aortic stenosis with medical and surgical management: importance of STS Score at diagnosis. Ann Thorac Surg 2010;90:1876-83.
6. Monin JL, Lancellotti P, Monchi M, et al. Risk score for predicting outcome in patients with asymptomatic aortic stenosis. Circulation 2009;120:69-75.
7. Rossebø AB, Pedersen TR, Allen C, et al. Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. Am J Cardiol 2007;99:970-3. (Pubitemid 46483289)
8. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56.
9. Cramariuc D, Rieck AE, Staal EM, et al. Factors influencing left ventricular structure and stresscorrected systolic function in men and women with asymptomatic aortic valve stenosis (a SEAS substudy). Am J Cardiol 2008;101:510-15. (Pubitemid 351199446)
10. Cox DR. Two further applications of a model for binary regression. Biometrika 1958;45:562-5.
11. Lemeshow S, Hosmer DW. The use of goodness-of-fit statistics in the development of logistic regression models. Am J Epidemiol 1982;115:92-106. (Pubitemid 12205725)
12. Arkes HR, Dawson NV, Speroff T, et al. The covariance decomposition of the probability score and its use in evaluating prognostic estimates. Med Dec Making 1995;15:120-31.
13. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task force on Practice Guidelines. J Am Coll Cardiol 2008;52:e1-142.
14. Cioffi G, Faggiano P, Vizzardi E, et al. Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. Heart 2011;97:301-7.
15. Ennezat PV, Maréchaux S, Iung B, et al. Exercise testing and exercise stress echocardiography in asymptomatic aortic valve stenosis. Heart 2009;95:877-84.
16. Vahainen A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: the task force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007;28:230-68. (Pubitemid 46276943)
17. McCann GP, Steadman CD, Ray SG, et al. Managing the asymptomatic patient with severe aortic stenosis: randomized controlled trial of early surgery are overdue. Heart 2011;97:1119-21.
18. Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997;95:2262-70. (Pubitemid 27191003)
19. Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611-17. (Pubitemid 30659472)
20. Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged followup. Circulation 2005;111:3290-5. (Pubitemid 40875002)
21. Franchini M, Targher G, Lippi G. Serum bilirubin levels and cardiovascular disease risk: a Janus Bifrons? Adv Clin Chem 2010;50:47-63.
22. Lin JP, Schwaiger JP, Cupples LA, et al. Conditional linkage and genome-wide association studies identify UGT1A1 as a major gene for ant-atherogenic serum bilirubin lebels-The Framingham Heart Study. Atherosclerosis 2009;206:228-33.
23. Cooney MT, Vartiainen E, Laatikainen T, et al. Simplifying cardiovascular risk estimation using resting heart rate. Eur Heart J 2010;31:2141-7.
24. Böhm M, Swedberg K, Komajda M, et al; on behalf of the SHIFT investigators. Heart rate as a risk factor in chronic heart failure: the association between heart rate and outcome in a randomized placebo controlled trial. Lancet 2010;376:886-94.
25. Ridker PM, Danielson E, Fonseca FA, et al; for the JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.